According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical trial to evaluate the antiviral effect on the reduction of viral load in patients with COVID-19. In this study, we aimed to investigate whether ciclesonide inhalation could eradicate SARS-CoV-2 compared to standard supportive care in patients with mild COVID-19.
Drug: Ciclesonide Metered Dose Inhaler [Alvesco]
Ciclesonide 320ug oral inhalation q12h for 14 days
Inclusion Criteria:
- Patients with mild COVID-19 (NEWS scoring system 0-4)
- Patient within 7 days from symptom onset or Patient within 48 hous after laboratory
diagnosis (SARS-CoV-2 RT-PCR)
Exclusion Criteria:
- Hypoxia (SaO2 <95%)
- Unable to take oral medication
- Unable to use inhaler
- Pregnancy or breast feeding
- Immunocompromising conditions
- Moderate/severe renal dysfunction : creatinine clearance (CCL) < 30 mL/min
- Moderate/severe liver dysfunction: AST or ALT > 5 times upper normal limit
- Asthma or chronic obstructive lung disease
Korea University Guro Hospital
Seoul, Korea, Republic of